Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14365/5916| Title: | Amivantamab Plus Lazertinib Vs Osimertinib in First Line, Egfr-Mutant Advanced Nsclc: Patientrelevant Outcomes From Mariposa |
| Authors: | Nguyen, D. Besse, B. Cho, B. C. Lee, S. -H. Lee, K. H. Lu, S. Garcia Campelo, M. R. |
| Publisher: | Elsevier Science inc |
| URI: | https://hdl.handle.net/20.500.14365/5916 |
| ISSN: | 1556-0864 1556-1380 |
| Appears in Collections: | WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
Sorry the service is unavailable at the moment. Please try again later.
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.